Physician profile
Sandra Lipovaca
NPI 1003144858
$195.70
in general payments reported to CMS, 2019-2025
6 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $25.09 · 2020: $50.35 · 2021: $73.77 · 2022: $46.49.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $51.42 | 2019-2021 | |
| Sanofi Pasteur INC. | $46.69 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $44.45 | 2019-2021 | |
| Pfizer INC. | $18.37 | 2021 | |
| Biomarin Pharmaceutical INC. | $17.46 | 2022 | |
| Boston Scientific Corporation | $17.31 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Lipovaca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.